Drug intelligence / Profile preview

DIGESTIX

Development stage: Unknown
Lead developer: IP Holdings
Modality: Microbiome Therapeutics
Administration: Oral

Overview

DIGESTIX is a gut microbiome modulator and dietary fiber developed by Xylonix IP Holdings. It is designed to address chronic systemic inflammation, autoimmune diseases, endotoxemia, and dysbiosis by restoring intestinal homeostasis and modulating the gut microbiota. The product is specifically formulated to synergize with activated charcoal, potentially enhancing the sequestration and clearance of pro-inflammatory endotoxins from the gastrointestinal tract. By reducing the systemic absorption of these toxins, DIGESTIX aims to mitigate inflammation associated with gut barrier dysfunction. It has reached an approved status in the developer's pipeline, positioned as a therapeutic intervention for conditions linked to gut health and systemic inflammatory responses.

Brand names: DIGESTIX
Other names: DIGESTIX

Beyond the preview

Go deeper on DIGESTIX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIGESTIX.

Explore the full profile